Compare Quest Diagnostics Inc (DGX) vs Flux Power Holdings Inc (FLUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Flux Power Holdings Inc — how do they compare? Quest Diagnostics Inc trades at $229.97 (market cap $25.48B), while Flux Power Holdings Inc trades at $0.46 (market cap $9.97M). The key difference: Quest Diagnostics Inc is far larger — about 2555.7× Flux Power Holdings Inc's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Flux Power Holdings Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Flux Power Holdings Inc for 20 Days on average.
| DGX | FLUX | |
|---|---|---|
Market Cap | $25.48B | $9.97M |
Volume | 941,866 | 817,320 |
Sector | Health | Industrials |
52-Week High | $247.45 | $6.66 |
52-Week Low | $173.49 | $0.41 |
Typical Hold Time | 56 Days | 20 Days |
Enterprise Value | $31.23B | $18.18M |
Dividend Yield | 1.49% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $230.76, up 1.66% today, reflecting strong year-to-date momentum driven by consistent earnings beats and growth in advanced diagnostics. The stock is near its 52-week high with a consensus price target of $250, indicating further upside potential. Recent news highlights partnerships, such as integration with Apple Health, and clinical study successes, though Medicare reimbursement cuts pose a headwind. Technical indicators show a bearish signal overall, with support at $228 and resistance at $232.
The outlook remains positive due to robust revenue growth, expanding profit margins, and strategic initiatives, but risks include regulatory pressure on lab payments and rising debt levels. Analyst sentiment is mixed, with a majority holding neutral ratings, suggesting cautious optimism amid execution challenges and market volatility.
FLUX trades at $0.4612, down 5.92% today, with a bearish technical signal despite unanimous analyst buy ratings. The company reported declining revenue from $66M in 2025 to $42M in 2026 while maintaining a net loss of -$7M. Recent news highlights a rejected acquisition offer from Solidion Technology, creating uncertainty around strategic direction.
The stock faces fundamental challenges with negative profitability metrics but maintains a low P/S ratio of 0.22. Investment opportunity exists if operational improvements materialize, while risks include persistent losses and acquisition-related volatility. Analyst consensus remains optimistic with 6 buy ratings despite recent earnings misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Flux Power Holdings Inc
Flux Power designs and manufactures lithium-ion battery packs for industrial vehicles. Its sustainable energy solutions power material handling equipment like forklifts and airport ground support vehicles.
Read more on FLUX →
